- Belo Sun to Commence Technical Studies on Volta Grande Gold Project
May 12, 2026
TORONTO, May 12, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or “Company”) (TSX: BSX, OTCQB: BSXGF) today announces the commencement of technical studies relating to its Volta Grande Gold Project (“Project”) located in Pará State, Brazil, with the engagement of a mining consultant and the hiring of a Engineering Director.
Belo Sun has engaged G Mining Services Inc. (“GMS”), a leading international mining consultancy with extensive engineering and project execution experience in Pará and across Latin America, to conduct a comprehensive Technical Gap Analysis (“TGA”) of the Project. GMS will systematically review and update the technical studies associated with the Project’s Installation License. The objectives of the TGA are to identify improvement opportunities, define the scope and sequencing for updates to the Definitive Feasibility Study (“DFS”), and provide the Company with an executable project plan structured as a staged development program.
The Company expects GMS to complete the TGA in the third quarter of 2026. The TGA will set the stage for an updated DFS which will reflect the latest planning work as well as the current economic environment and metal prices. The Company is targeting the completion of the DFS update in early 2027. Construction will start as soon as possible thereafter.
To ensure strong technical oversight and leadership of the technical studies and planning process, Belo Sun has appointed Adilson Araújo Laudares as Engineering Director for the Project. Mr. Laudares brings more than 29 years of experience from Vale S.A., where his responsibilities spanned planning, quality control, operation and management of multiple development-stage and operational mining projects. He holds a degree in Mining Engineering from the Federal University of Minas Gerais and obtained an MBA from Fundação Dom Cabral.
Clovis Torres, Chief Executive Officer of Belo Sun, commented: “The engagement of GMS to conduct a gap analysis represents a key step in advancing the Project toward construction. Throughout the planning phase, we will explore all opportunities to maximize benefits for stakeholders while advancing the Project responsibly. We welcome Adilson Laudares to our team to oversee these crucial activities and move forward with our Project.”
About G Mining Services
G Mining Services Inc. is a specialized Canadian mining consultancy founded in 2006, with extensive experience in open-pit and underground mining projects from greenfield development through to construction, commissioning, and operations. GMS has directly managed engineering, procurement, construction, pre-production, and commissioning of projects in West Africa, South America, and North America, including the Tocantinzinho Project in Pará, Brazil.
The TGA will be supported by a GMS multi-disciplinary team with expertise in geology, mining engineering, metallurgy & process, infrastructure, engineering, and project controls.
About the Company
Belo Sun Mining Corp. is a mineral exploration and development company with gold-focused properties in Brazil. Belo Sun’s primary focus is advancing and expanding its 100% owned Volta Grande Gold Project in Pará State, Brazil. Belo Sun trades on the TSX under the symbol “BSX” and on the OTCQB under the symbol “BSXGF.” For more information about Belo Sun, please visit www.belosun.com.
For inquiries, please contact Belo Sun Mining Corp, +1 888-516-4171 or info@belosun.com.
Caution regarding forward-looking information:
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the engagement of GMS to conduct the TGA, including the expected timing, scope and outcome thereof; the scope, sequencing and expected timing for completion of the updated DFS; the appointment of key personnel to oversee the technical studies and planning process; the continued effectiveness of the reissued Installation License (LI No. 3698/2026) and the Company’s ability to satisfy the conditions thereunder; expectations regarding the commencement and timing of construction activities; and the future development of the Volta Grande Project. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information, including, without limitation, risks that the TGA may identify technical, environmental or other issues requiring additional studies, time or expenditure beyond current expectations; risks that the updated DFS may yield materially different results, project parameters or economic outcomes than those presented in the 2015 DFS; risks that the LI may be challenged, modified, suspended or revoked; risks relating to the Company’s ability to satisfy the conditions of the LI, including the timing and outcome of updated technical assessments and SEMAS’s review thereof; risks relating to legal or regulatory proceedings affecting the Project; risks relating to Indigenous and community consultation; risks relating to the timing, scope, cost and outcome of the updated DFS and the assumptions underlying it (including with respect to gold prices, capital and operating cost estimates and metallurgical recoveries); risks relating to the Company’s ability to recruit, train and retain qualified personnel, including local workforce; risks relating to the Company’s ability to obtain financing on acceptable terms, or at all, to advance the Project; risks relating to gold price volatility, foreign exchange rates and inflation; risks relating to changes in applicable laws, regulations or government policies in Brazil; risks inherent in the mining and mineral exploration and development industry generally and risks described in the public disclosure of the Company which is available under the profile of the Company on SEDAR+ at www.sedarplus.caand on the Company's website at www.belosun.com. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
- Belo Sun to Commence Technical Studies on Volta Grande Gold Project
May 12, 2026 · globenewswire.com
TORONTO, May 12, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or “Company”) (TSX: BSX, OTCQB: BSXGF) today announces the commencement of technical studies relating to its Volta Grande Gold Project (“Project”) located in Pará State, Brazil, with the engagement of a mining consultant and the hiring of a Engineering Director.
- BELO SUN TO COMMENCE TECHNICAL STUDIES ON VOLTA GRANDE GOLD PROJECT
May 12, 2026
TORONTO, MAY 12, 2026 (GLOBE NEWSWIRE) -- BELO SUN MINING CORP. (“BELO SUN” OR “COMPANY”) (TSX: BSX, OTCQB: BSXGF) TODAY ANNOUNCES THE COMMENCEMENT OF TECHNICAL STUDIES RELATING TO ITS VOLTA GRANDE GOLD PROJECT (“PROJECT”) LOCATED IN PARÁ STATE, BRAZIL, WITH THE ENGAGEMENT OF A MINING CONSULTANT AND THE HIRING OF A ENGINEERING DIRECTOR.
- 3 Growth Stocks to Add to Your Roster
May 12, 2026
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.
Deciphering which businesses can sustain their high growth rates is a challenge for even the most seasoned professionals, which is why we started StockStory. Keeping that in mind, here are three growth stocks where the best is yet to come.
Alphabet (GOOGL)
One-Year Revenue Growth: +17.5%
Started by Stanford students Larry Page and Sergey Brin in a Menlo Park garage, Alphabet (NASDAQ:GOOGL) is the parent company of the eponymous Google Search engine, Google Cloud Platform, and YouTube.
Why Is GOOGL a Good Business?
Alphabet’s dominant Google Search sits on the pantheon of the best businesses ever. This is reflected in its robust long-term revenue growth and elite operating margin. The company’s profit margins have become even higher over time, speaking to its scale advantages and operating efficiency not only in its core Search business but also in Google Cloud Platform and YouTube. Revenue growth and increasing operating margins are the key ingredients for strong EPS growth. Google has these, and when also factoring in its share repurchases, you can see why EPS has exploded over the long term.
Alphabet is trading at $396.80 per share, or 31.7x forward price-to-earnings. Is now a good time to buy? See for yourself in our in-depth research report, it’s free.
Boston Scientific (BSX)
One-Year Revenue Growth: +17.4%
Founded in 1979 with a mission to advance less-invasive medicine, Boston Scientific (NYSE:BSX) develops and manufactures medical devices used in minimally invasive procedures across cardiovascular, urological, neurological, and gastrointestinal specialties.
Why Are We Positive On BSX?
Average organic revenue growth of 15.7% over the past two years demonstrates its ability to expand independently without relying on acquisitions Additional sales over the last five years increased its profitability as the 24.2% annual growth in its earnings per share outpaced its revenue Free cash flow margin increased by 9.1 percentage points over the last five years, giving the company more capital to invest or return to shareholders
Boston Scientific’s stock price of $56.33 implies a valuation ratio of 16.2x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.
Bowhead Specialty (BOW)
One-Year Revenue Growth: +27.7%
Named after the Arctic bowhead whale known for navigating challenging waters, Bowhead Specialty Holdings (NYSE:BOW) is a specialty insurance company that provides customized coverage for complex and high-risk commercial sectors.
Story Continues
Why Are We Backing BOW?
Net premiums earned surged by 33.5% annually over the past two years, reflecting strong market share gains this cycle Earnings per share grew by 42.9% annually over the last three years and trumped its peers Annual book value per share growth of 29.1% over the past two years was outstanding, reflecting strong capital accumulation this cycle
At $26.34 per share, Bowhead Specialty trades at 1.6x forward P/B. Is now the right time to buy? See for yourself in our comprehensive research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
View Comments
- [Latest] Global Flexible Endoscope Market Size/Share Worth USD 22.7 Billion by 2035 at a 6% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
May 11, 2026
Custom Market Insights
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Flexible Endoscope Market size & share revenue was valued at approximately USD 12.7 Billion in 2025 and is expected to reach USD 13.5 Billion in 2026 and is expected to reach around USD 22.7 Billion by 2035, at a CAGR of 6% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Olympus Corporation, Cook Medical Inc., Becton Dickinson and Company, Boston Scientific Corporation, Cantel Medical Corporation, Conmed Corporation, B. Braun SE, EndoMed Systems GmbH, Firefly Global, Fujifilm Holdings Corporation, H.W.Andersen Products Ltd., Hoya Corporation, Intuitive Surgical Inc., Karl Storz SE & Co. KG, Machida Endoscope Co. Ltd, Ambu A/S and others.
Austin, TX, USA, May 11, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Flexible Endoscope Market Size, Trends and Insights By Product (Bronchoscopes, Laparoscopes, Otoscopes, Laryngoscopes, Cystoscopes, Ureteroscopes, Arthroscopes, Nasopharyngoscopes, Neuroendoscopes, Rhinoscopes, Gastrointestinal Endoscopes, Hysteroscopes, Gynecology Endoscopes), By End Use (Hospitals, Outpatient Facilities), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2026 – 2035” in its research database.
According to the latest research study, the global Flexible Endoscope Market was valued at approximately USD 12.7 billion in 2025 and is expected to reach USD 13.5 billion in 2026, with a projected value of around USD 22.7 billion by 2035, at a compound annual growth rate (CAGR) of about 6% during the forecast period from 2026 to 2035.
Click Here to Access a Free Sample Report of the Global Flexible Endoscope Market @ https://www.healthcareforesights.com/request-customization?reportId=1002Flexible Endoscope Market 2026 – 2035
Flexible Endoscope Market Revenue and Trends
A flexible endoscope is a medical tool that looks inside the body, finds problems, and treats them without making big cuts or through small openings.It has a long, thin, and flexible insertion tube that contains a light source, a high-resolution camera or a fiber-optic imaging system, and one or more working channels for instruments used in biopsy, suction, irrigation, or therapeutic procedures.. Flexible endoscopes' ability to bend and navigate through complex anatomical pathways makes them perfect for examining different parts of the body, such as the gastrointestinal tract, respiratory system, urinary tract, and other delicate structures. They are involved with many procedures including gastroscopy, colonoscopy, bronchoscopy, and cystoscopy and are central to the whole process of minimally invasive diagnostics and treatment that depends on real-time visualization with fair patient comfort level, quicker recovery, and lower risk compared to traditional surgical techniques. The market growth is driven by several factor such as increasing prevalence of cancer, growing product launch and increasing investment in emerging markets by the key market players.
Story Continues
Request a Customized Copy of the Flexible Endoscope Market Report @https://www.healthcareforesights.com/request-sample?reportId=1002
What factors significantly contribute to the growth of the flexible endoscope market?
The flexible endoscopes market is experiencing significant growth due to an amalgamation of various factors like clinical, technological, economic, and regulatory which in turn are increasing the number of procedures and speeding up the adoption of equipment across the different healthcare sectors.
The global burden of diseases affecting the gastrointestinal and respiratory systems which are very painful and expensive to treat as they include conditions like GERD, colorectal cancer, inflammatory bowel disease, COPD, and lung infections is also one of the main factors that is driving the endoscope market. Controlling and monitoring the diseases through endoscopic means requires frequent diagnosis and monitoring. Besides this, the industry is also turning to the less challenging method of open surgeries, i.e. flexible endoscopy, to do less harm to the patients and cut hospital stays and treatment costs.
In addition, medical science is advancing rapidly in technology, which is also a major factor driving the endoscope market. The introduction of high-definition and 4K imaging, along with better visualization techniques, AI-powered lesion detection, and advanced tissue imaging (optical biopsy), improves diagnostic accuracy and builds clinical confidence, making hospitals more likely to upgrade or replace their old systems. More focus on infection control and patient safety has also led to faster adoption of single-use flexible endoscopes and endoscopes with disposable parts, thus creating new revenue streams and penetrating high-risk procedures more effectively.
(A free sample of the Flexible Endoscope report is available upon request; please contact us for more information.)
Our Free Sample Report Consists of the following:
The updated report for 2026 includes an introduction, an overview, and an in-depth industry analysis. Provide detailed chapter-by-chapter guidance on the Request. Updated Regional Analysis with a Graphical Representation of Size, Share, and Trends for the Year 2026 Includes tables and figures that have been updated. The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis Healthcare Foresights (HEALTHCARE FORESIGHTS) research methodology
Request a Customized Copy of the Flexible Endoscope Market Report @https://www.healthcareforesights.com/reports/flexible-endoscope-market
Segment Insight
By Product
The gynecology endoscopes segment is growing at a significant rate over the projected period. The growing number of gynecological disorders, such as uterine fibroids, endometriosis, polycystic ovary syndrome (PCOS), and cancers of the cervix and uterus, is the main reason for the growth of this market. Patients suffering from such diseases invariably require the diagnostic and therapeutic endoscopic interventions of the highest order. As awareness of women’s health issues grows and screening and early intervention programs expand, mere reliance on flexible endoscopes for procedures translates into a large volume of procedures and, consequently, sales of the related equipment.
Request a Customized Copy of the Flexible Endoscope Market Report @ https://www.healthcareforesights.com/reports/flexible-endoscope-market
Key questions answered in this report:
What is the size of the Flexible Endoscope market, and what is its expected growth rate? What are the primary driving factors that push the Flexible Endoscope market forward? What are the Flexible Endoscope Industry's top companies? What are the different categories that the Flexible Endoscope Market caters to? What will be the fastest-growing segment or region? In the value chain, what role do key players play? What is the procedure for getting a free copy of the sample report for the Flexible Endoscope market and company profiles?
Buy Now Flexible Endoscope Market Report @ https://www.healthcareforesights.com/checkout/1002
Key Offerings:
Market Share, Size & Forecast by Revenue | 2026−2035 Market Dynamics – Growth Drivers, Restraints, Investment Opportunities, and Leading Trends Market Segmentation – A detailed analysis by Types of Services, by End-User Services, and by regions Competitive Landscape – Top Key Vendors and Other Prominent Vendors
Buy this Premium Flexible Endoscope Research Report | Fast Delivery Available - [220+ Pages] @ https://www.healthcareforesights.com/reports/flexible-endoscope-market
Regional Insights
The flexible endoscope market has been dominated by North America. The North America region has also been supported by advanced healthcare infrastructure, government initiatives that are conducive to healthcare, and optimum treatment coverage.
Besides, the Asia-Pacific market has the highest growth rate in the flexible endoscope market. The major influencing factor for this upsurge is the heavy burden of the target illnesses, and the expectation of a significant patient group is also going to help the growth of the area. The healthcare infrastructure in the region is improving, with increased investment from market players primarily driven by the booming demand for medical devices in the APAC region, leading to a certain degree of growth.
Request a Customized Copy of the Flexible Endoscope Market Report @ https://www.healthcareforesights.com/reports/flexible-endoscope-market
We customize your report to align with your specific research requirements. Inquire with our sales team about customizing your report.)
Still Looking for More Information? Do you want data for inclusion in magazines, case studies, research papers, or media?
Email Directly Here with Detailed Information: support@custommarketinsights.com
Browse the full “Flexible Endoscope Market Size, Trends and Insights By Product (Bronchoscopes, Laparoscopes, Otoscopes, Laryngoscopes, Cystoscopes, Ureteroscopes, Arthroscopes, Nasopharyngoscopes, Neuroendoscopes, Rhinoscopes, Gastrointestinal Endoscopes, Hysteroscopes, Gynecology Endoscopes), By End Use (Hospitals, Outpatient Facilities), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2026 – 2035” Report at https://www.healthcareforesights.com/reports/flexible-endoscope-market
Report Scope
Feature of the Report Details Market Size in 2026 USD 13.5 billion Projected Market Size in 2035 USD 22.7 billion Market Size in 2025 USD 12.7 billion CAGR Growth Rate 6% CAGR Base Year 2025 Forecast Period 2026-2035 Key Segment By Product, End Use and Region Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America Buying Options Request tailored purchasing options to fulfil your requirements for research.
Recent Developments
In August 2024, KARL STORZ United States, a global leader in Operating Room (OR) integration, teamed up with FUJIFILM Healthcare Americas Corporation (Fujifilm), a major maker of endoscopic imaging and endosurgical products, to provide a wide range of solutions for both endoscopists and surgeons. The two companies will together promote Fujifilm’s exceptional flexible gastrointestinal (GI) endoscopes and KARL STORZ’s unmatched OR integration solutions. The partnership between Fujifilm and KARL STORZ will help upgrade surgical ORs, routine and interventional hospital GI suites, and ambulatory surgery centers (ASCs) with innovative OR integration and state-of-the-art flexible endoscopes in areas where most GI and surgical OR procedures are done. (Source: https://www.biopharmaapac.com/news/77/5181/karl-storz-and-fujifilm-healthcare-partner-to-enhance-gi-endoscopy-and-or-integration.html)
Click Here to Access a Free Sample Report of the Global Flexible Endoscope Market @ https://www.healthcareforesights.com/reports/flexible-endoscope-market
Spectacular Deals
Comprehensive coverage Maximum number of market tables and figures The subscription-based option is offered. Best price guarantee Free 35% or 60 hours of customization. Free post-sale service assistance. 25% discount on your next purchase. Service guarantees are available. A personalized market brief by the author.
Browse More Related Reports:
Henatologic Malignancies Testing Market
US Clinical Trial Supplies Market
Ear Health Market
Fluorescent In Situ Hybridization Probe Market
Laboratory Equipment Services Market
Synthetic Bone Graft Substitutes Market
Japan Epigenetics Market
US Cell-Based Assays Market
Therapeutic Plasma Exchange Market
Therapeutic Apheresis MarketNorth America Flexible Endoscope Market Size 2025 to 2035 (USD Billion)
List of the prominent players in the Flexible Endoscope Market:
Olympus Corporation Cook Medical Inc. Becton Dickinson and Company Boston Scientific Corporation Cantel Medical Corporation Conmed Corporation B. Braun SE EndoMed Systems GmbH Firefly Global Fujifilm Holdings Corporation H.W. Andersen Products Ltd. Hoya Corporation Intuitive Surgical Inc. Karl Storz SE & Co. KG Machida Endoscope Co. Ltd Ambu A/S Others
The Flexible Endoscope Market is segmented as follows:
By Product
Bronchoscopes Laparoscopes Otoscopes Laryngoscopes Cystoscopes Ureteroscopes Arthroscopes Nasopharyngoscopes Neuroendoscopes Rhinoscopes Gastrointestinal Endoscopes Hysteroscopes Gynecology Endoscopes
By End Use
Hospitals Outpatient Facilities
Click Here to Get a Free Sample Report of the Global Flexible Endoscope Market @ https://www.healthcareforesights.com/reports/flexible-endoscope-market
Regional Coverage:
North America
U.S. Canada Mexico Rest of North America
Europe
Germany France U.K. Russia Italy Spain Netherlands Rest of Europe
Asia Pacific
China Japan India New Zealand Australia South Korea Taiwan Rest of Asia Pacific
The Middle East & Africa
Saudi Arabia UAE Egypt Kuwait South Africa Rest of the Middle East & Africa
Latin America
Brazil Argentina Rest of Latin America
This Flexible Endoscope Market Research/Analysis Report Contains Answers to the following Questions.
Which Trends Are Causing These Developments? Who Are the Global Key Players in This Flexible Endoscope Market? What are the company profiles, product information, and contact details for these key players? What Was the Global Market Status of the Flexible Endoscope Market? What Was the Capacity, Production Value, Cost, and PROFIT of the Flexible Endoscope Market? What Is the Current Market Status of the Flexible Endoscope Industry? What's the market's competition in this industry, both company-wise and country-wise? What is the market analysis of the flexible endoscope market, considering its applications and types? What Are Projections of the Global Flexible Endoscope Industry Considering Capacity, Production, and Production Value? What Will Be the Estimate of Cost and Profit? What Will Be the Market Share, Supply, and Consumption? What about imports and exports? What is a Flexible Endoscope market chain analysis of upstream raw materials and downstream industries? What is the economic impact on the Flexible Endoscope industry? What are Global Macroeconomic Environment Analysis Results? What Are Global Macroeconomic Environment Development Trends? What Are the Market Dynamics of the Flexible Endoscope Market? What Are Challenges and Opportunities? What Should Be Entry Strategies, Countermeasures to Economic Impact, and Marketing Channels for the Flexible Endoscope Industry?
Click Here to Access a Free Sample Report of the Global Flexible Endoscope Market @ https://www.healthcareforesights.com/reports/flexible-endoscope-market
Reasons to Purchase Flexible Endoscope Market Report
The Flexible Endoscope Market Report gives both qualitative and quantitative analysis of the market by looking at economic and non-economic factors. Flexible Endoscope: The market report outlines the market value (in USD) data for each segment and sub-segment. This report indicates the region and segment expected to witness the fastest growth and dominate the market. Flexible Endoscope Market Analysis by geography highlights the consumption of the product/service in the region and indicates the factors affecting the market within each region. The competitive landscape incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled. Extensive company profiles comprise a company overview, company insights, product benchmarking, and SWOT analysis for the major market players. Recent developments, including growth opportunities and drivers, as well as challenges and restraints in both emerging and developed regions, shape the industry's current and future market outlook. Flexible Endoscope Market: Includes in-depth market analysis from various perspectives through Porter's five forces analysis and offers an overview of the market through the value chain.
Reasons for the Research Report
The study provides a thorough overview of the global Flexible Endoscope market. Compare your performance to that of the market as a whole.
Aim to maintain competitiveness while innovations from established leaders drive market growth.
Buy this Premium Flexible Endoscope Research Report | Fast Delivery Available - [220+ Pages] @ https://www.healthcareforesights.com/reports/flexible-endoscope-market
What does the report include?
Drivers, restrictions, and opportunities are among the qualitative elements covered in the worldwide Flexible Endoscope market analysis.
The report covers the competitive environment of current and potential participants in the Flexible Endoscope market, along with their strategic product development ambitions.
This study conducts a qualitative and quantitative analysis of the Flexible Endoscope market based on the component, application, and industry vertical. Additionally, the report provides comparable data for the key regions.
The report provides actual market sizes and forecasts for each segment mentioned above.
Who should buy this report?
Participants and stakeholders in the worldwide flexible endoscope market should find this report useful. The research will be useful to all market participants in the Flexible Endoscope industry.
Managers in the Flexible Endoscope sector are interested in publishing up-to-date and projected data about the worldwide Flexible Endoscope market.
Governmental agencies, regulatory bodies, decision-makers, and organizations want to invest in Flexible Endoscope products' market trends.
Analysts, researchers, educators, strategy managers, and government organizations seek market insights to develop plans.
Request a Customized Copy of the Flexible Endoscope Market Report @ https://www.healthcareforesights.com/reports/flexible-endoscope-market
About Healthcare Foresights:
Healthcare Foresights is a market research and advisory company delivering business insights and market research reports to large, small, and medium-scale enterprises. We assist clients with strategies and business policies and regularly work towards achieving sustainable growth in their respective domains.
Healthcare Foresights is a one-stop solution for data collection and investment advice. Our company's expert analysis digs out essential factors that help us understand the significance and impact of market dynamics. The professional experts advise clients on aspects such as strategies for future estimation, forecasting, opportunities to grow, and consumer surveys.
Follow Us: LinkedIn | Twitter | Facebook | Instagram
Contact Us:
Frank Gittens
CMI Consulting LLC
701 Tillery Street Unit 12-1333
Austin, Texas 78702
United States
USA: +1 737-734-2707
APAC: +91 20 46022736
WhatsApp No : +1 801 639 9061
Email: support@healthcareforesights.com
Blog: https://www.healthcareforesights.com/
Buy this Premium Flexible Endoscope Research Report | Fast Delivery Available - [220+ Pages] @ https://www.healthcareforesights.com/reports/flexible-endoscope-market
View Comments
- Boston Scientific: Poised To Rebound With The Healthcare Sector, But When?
May 11, 2026 · seekingalpha.com
Boston Scientific Corporation is a leading medtech innovator facing recent share price underperformance due to market share erosion in electrophysiology and sector-wide sentiment shifts. Despite competitive pressures, BSX maintains strong leadership in PFA, with Watchman and neuromodulation as promising growth drivers and a robust pipeline supported by strategic M&A. Management has improved operating and net margins, reduced short-term debt, and achieved ROIC above WACC, signaling efficient capital allocation and resilience despite slowing revenue growth.
- Abbott Laboratories: Mispriced Growth Behind Near-Term Noise?
May 9, 2026
This article first appeared on GuruFocus.
Abbott Laboratories stands as a cornerstone of the global healthcare landscape, possessing a legacy that spans over 135 years of continuous operation and a financial track record characterized by relentless dividend growth and strategic agility. As the organization navigates the post-pandemic era, it has transitioned from a critical provider of infectious disease diagnostics to a leader in chronic disease management and precision medicine. The release of the fourth-quarter 2025 financial results underscores a period of tactical repositioning, where the company is balancing the exceptional growth of its medical device portfolio against the structural headwinds in its nutritional division and the multi-billion-dollar integration of Exact Sciences. This analysis evaluates Abbott's fundamental business architecture, the nuances of its recent operational performance, and the underlying investment thesis that continues to attract institutional interest despite recent valuation compression.
Diversification as a Defensive Moat
Is ABT fairly valued? Test your thesis with our free DCF calculator.
The operational strength of Abbott Laboratories is rooted in its four-pillared business model, which segments the enterprise into Medical Devices, Diagnostics, Established Pharmaceuticals (EPD), and Nutrition. This structural diversification acts as an internal hedge; while the high-margin, innovation-driven medical device segment captures the market's growth premium, the consumer-facing nutrition and branded generic pharmaceutical segments provide a consistent, defensive cash flow profile. This "quadrant" approach allows the company to maintain a steady growth trajectory even when specific verticals face regulatory or macroeconomic challenges.
The company's global reach is equally vast, with operations in over 160 countries. This international footprint is a critical component of Abbott's competitive advantage, particularly in the Established Pharmaceuticals Division, where the company focuses exclusively on emerging markets. By avoiding the price-capped mature markets of the U.S. and Western Europe for generics, Abbott captures the rising demand for reliable, high-quality medication in countries like India, where EPD has achieved consistent double-digit growth. In the high-tech segments, such as Medical Devices, the global presence ensures that innovations like the FreeStyle Libre system can be rapidly scaled across diverse reimbursement environments, maximizing the return on R&D investments.
Story Continues
Decoding the Fourth Quarter of 2025
The fourth quarter of 2025 presented a complex narrative of operational resilience set against top-line pressures. Abbott reported total net sales of $11.459 billion, an increase of 4.4% on a reported basis and 3.0% on an organic basis. When excluding the impact of COVID-19 testing-related sales, which continued their terminal decline, organic growth reached 3.8%. Despite this steady growth, the top-line result was a miss compared to analyst expectations of approximately $11.8 billion, leading to a temporary contraction in the share price.Abbott Laboratories: Mispriced Growth Behind Near-Term Noise?
The divergence between the revenue miss and the bottom-line strength is the defining characteristic of this quarter. Adjusted diluted EPS grew 12% to $1.50, successfully meeting market expectations and demonstrating management's ability to defend profitability through aggressive margin management. The operating margin expansion to 25.8%, a 150-basis-point improvement, was particularly noteworthy given the persistent inflationary pressures and the costs associated with the Exact Sciences acquisition. This expansion reflects a disciplined approach to P&L leverage, where the company is successfully shifting its mix toward higher-margin medical devices while simultaneously optimizing the cost structure in its foundational businesses.
The Medical Device Growth Engine
Medical Devices remained the primary engine of value creation for Abbott in the final months of 2025. The segment recorded sales of $5.675 billion, representing a 12.3% reported increase and 10.4% organic growth. This performance marked the 12th consecutive quarter of double-digit organic growth, a streak that distinguishes Abbott from many of its large-cap medtech peers.
FreeStyle Libre continuous glucose monitoring (CGM) system continues to be the dominant force in the portfolio. In Q4, CGM sales grew 12.2% organically to $2.0 billion.13 For the full year 2025, Libre sales surpassed the $7.5 billion mark, marking the third year in a row where the product added more than $1 billion in incremental revenue. The strategic focus is now shifting toward the massive opportunity in the non-insulin-using Type 2 diabetes population. Management is preparing for an expansion of CMS coverage for these patients in the first half of 2026, which could significantly increase the total addressable market for CGM technology. Furthermore, the launch of Lingo, an over-the-counter CGM for health-conscious consumers, represents Abbott's foray into the bio-wearable market, aiming to leverage medical technology for general wellness.
The electrophysiology (EP) sub-segment is undergoing a technological shift toward Pulsed Field Ablation, a safer and more precise method for treating atrial fibrillation (AFib). Abbott has positioned itself as a disruptor in this space with the FDA approval of the Volt PFA System and the CE Mark for the TactiFlex Duo ablation catheter. The company's "toolbox" strategy, offering physicians a choice between radiofrequency and PFA energy within the same catheter system, is designed to capture market share from incumbents who lack this flexibility. EP sales grew double-digits in both the U.S. and international markets during the quarter, signaling a strong reception for these new technologies.
Abbott's structural heart portfolio, which includes the Navitor TAVR valve and the TriClip for tricuspid regurgitation, achieved double-digit growth fueled by new product launches and expanded indications. In rhythm management, the Aveir leadless pacemaker has been a standout performer, growing 12% in the quarter. With only a 10% penetration in the $5 billion global pacemaker market, the leadless category represents a significant long-term growth vertical as it addresses the complication risks associated with traditional lead-based systems.
Volume Growth through Nutrition Segment Recovery
The Nutrition segment, historically a source of stability, was the primary detractor from Abbott's top-line performance in late 2025. Worldwide nutrition sales fell 8.9% on a reported basis and 9.1% organic. This decline was driven by a 13.2% drop in U.S. sales, where the pediatric business faced challenges including the loss of a major WIC contract and broader market share erosion.
Management has been transparent about the mechanism behind this downturn. Post-pandemic inflation led to higher manufacturing costs, which the company passed on to consumers through higher prices. However, this pricing power eventually reached a point of diminishing returns, where price sensitivity suppressed volume growth. To rectify this, Abbott has implemented a "reignition" strategy focused on price and promotion initiatives intended to regain market share, even at the cost of short-term revenue growth. A robust pipeline of eight new products in the next year is expected to support this recovery, with management forecasting a return to growth for the division in the second half of 2026.
The Diagnostic Segment's Evolution
The Diagnostics segment reported a sales decline of 2.5% reported and 3.6% organic in Q4. However, this figure is heavily distorted by the anticipated roll-off of COVID-19 testing, which plummeted from $176 million in the prior-year quarter to just $89 million in late 2025. When stripping out these volatile pandemic-era revenues, the underlying business shows a healthier trajectory.
The Core Laboratory Diagnostics division, the segment's long-term growth driver, grew 5.3% reported and 3.6% organic in the quarter. Excluding the impact of the challenging operating environment in China, where volume-based procurement (VBP) policies have squeezed pricing, Core Lab growth was 7%. The Alinity automation platform remains the central competitive advantage here, as it allows hospitals to consolidate their testing onto a single, highly efficient system, creating high switching costs and a steady stream of recurring revenue from consumables.
The most transformative strategic action in the diagnostics vertical is the acquisition of Exact Sciences, which officially closed on March 23, 2026. The $23 billion deal marks Abbott's definitive entry into the $60 billion U.S. cancer screening and precision oncology market. By acquiring Cologuard (the leading non-invasive colorectal cancer test) and Oncotype DX (breast cancer treatment guidance), Abbott is adding a high-growth vertical that is immediately accretive to its organic sales growth.
The intrinsic value of this acquisition lies in the synergy between Exact Sciences' product innovation and Abbott's global commercial scale. Exact Sciences' sales have historically been concentrated in the United States. By utilizing Abbott's massive international distribution network across 160 countries, the company can accelerate the adoption of cancer screening tools in emerging and developed markets where cancer incidence is rising but early detection tools are underutilized. Furthermore, the potential to host Exact Sciences' molecular assays on the Alinity platform could transform the workflow for hospitals globally, further entrenching Abbott as the preferred partner for complex diagnostics.
Branded Generics in Emerging Markets
The Established Pharmaceuticals Division (EPD) continues to be an underappreciated pillar of Abbott's business model. In Q4 2025, the segment grew 9.0% reported and 7.0% organic. This marked the fifth consecutive year that EPD delivered organic growth exceeding 7%, a level of consistency rarely seen in the generics industry.
Abbott's success in EPD is a result of its deliberate decision to avoid the commoditized, price-sensitive generic markets of the United States. Instead, the company focuses on a portfolio of branded generics in high-growth emerging markets including India, Brazil, Russia, and Southeast Asia. In these regions, consumers and healthcare providers often prefer branded versions of generic drugs due to concerns about quality and consistency. By branding its generics, Abbott captures a price premium and builds significant brand equity with physicians. Looking forward, EPD is expanding into biosimilars in emerging markets, targeting the fastest-growing generic segment and positioning itself to capture the long-term trend toward biologic medicines in the developing world.
Forward Guidance and 2026 Outlook
For the full year 2026, management has issued an outlook that implies a re-acceleration of the business. Abbott projects organic sales growth in the range of 6.5% to 7.5%. This guidance includes the anticipated recovery of the nutrition business in the second half of the year and the initial incremental sales from the Exact Sciences acquisition.
The company's ability to meet these targets will depend heavily on its continued margin expansion. Abbott is targeting 50 to 70 basis points of annual operating margin improvement, driven by gross margin expansion as the product mix shifts toward high-tech devices and oncology diagnostics. While the acquisition of Exact Sciences will be dilutive to adjusted EPS by approximately $0.20 in 2026, the long-term accretion to both the top line and gross margins is expected to outweigh this near-term pressure.
Valuation Analysis
The Sum-of-the-Parts Framework
To understand Abbott's true worth, we must move beyond the blended multiple. As a diversified conglomerate, Abbott houses businesses with vastly different growth profiles and capital requirements. By applying peer-group multiples to the estimated earnings contribution of each segment, we can determine the enterprise's intrinsic value.
Medical Devices: The Innovation Engine (Premium Multiple)
Medical Devices is Abbott's crown jewel, contributing $21.39 billion in 2025 revenue. With the FreeStyle Libre CGM system achieving its third consecutive year of $1 billion+ incremental growth, this segment rivals pure-play medtech innovators.
Peer Comparison: Stryker (SYK) and Boston Scientific (BSX) trade at forward P/Es ranging from 20x to 22.1x.
Segment EBIT Contribution: Based on historical margins and segment momentum, we estimate this unit contributes approximately 55% of corporate net income.
Diagnostics & Life Sciences: The Oncology Pivot (High Multiple)
With the closing of the $23 billion Exact Sciences deal in March 2026, Abbott now controls the $60 billion U.S. cancer screening market.
Peer Comparison: High-performance life sciences peers like Danaher (DHR) and Thermo Fisher (TMO) trade at 21.0x to 22.5x forward earnings.
Segment EBIT Contribution: Diagnostics and Life Sciences represent approximately 20% of normalized net income post-acquisition.
Nutrition: The Defensive Staple (Discounted Multiple)
These segments represent the mature "staple" side of Abbott. Nutrition is currently in a "reignition" phase to regain market share, while EPD continues to deliver steady 7%+ organic growth in emerging markets.
Peer Comparison: Best compared to consumer staples like Nestle (22x P/E) or Danone (18x P/E). Emerging generic drug peers like Viatris trade much lower (~5.5x), but Abbott's "branded generic" model in high-growth territories justifies a premium over commoditized generics.
Implied Value: We apply a conservative 15x multiple to reflect the current volume challenges in Nutrition.
At a current market capitalization of approximately $145 billion, Abbott trades at a significant discount to its peer-weighted components. If an investor buys the entire business today at 16x forward earnings, they are essentially paying a fair price for the Nutrition and EPD segments, while acquiring the high-growth, high-multiple Medical Device and Oncology segments at a 20-25% discount relative to their pure-play medtech peers.
Intrinsic Value: Beyond the Market Multiple
Independent of market sentiment, a 2-stage Free Cash Flow to Equity (FCFE) model provides a grounded estimate of Abbott's worth. With trailing twelve-month free cash flow of $7.26 billion and analyst projections reaching $11.46 billion by 2028, the discounted value of these future flows points to an intrinsic value of approximately $136.14 per share.
At a current price of ~$85, investors are purchasing the business at a 35% discount to its cash-generative power. The "conglomerate discount" appears to have reached an extreme, where the market has over-emphasized short-term headwinds in Nutrition while underestimating the compounding power of the Exact Sciences integration.
Two Paths to Value Realization
The value can be unlocked through two distinct strategic paths:
Path A: Operational Execution and the Oncology Halo
If Abbott successfully integrates Exact Sciences and achieves the projected $100 million in annual synergies by 2028, the blended corporate growth rate will naturally accelerate. As the Medical Device and Diagnostics segments come to represent a larger portion of the total revenue mix, the market may "naturally" re-rate the company higher to reflect its shift toward being a high-tech healthcare innovator rather than a diversified conglomerate.
Path B: Structural Unlock (The "GE/Danaher" Precedent)
If the conglomerate discount persists, management has a proven playbook for unlocking value: separation. Precedent exists within the company's own history; the 2013 spin-off of AbbVie unlocked massive shareholder value by separating the high-growth proprietary drug pipeline from the stable base business. Other industrials and healthcare peers like General Electric and Danaher have successfully utilized spin-offs to allow individual segments to trade at their "true" pure-play multiples. Path B suggests that even without market cooperation, Abbott possesses the structural flexibility to realize sum-of-the-parts value.
Guru Sentiment and Institutional Flows
The movement of top-tier institutional investors (gurus) provides critical context for the recent stock price volatility. During the second half of 2025, there was a notable divergence in how major hedge funds and asset managers viewed the ABT opportunity.
T. Rowe Price Investment Management: Doubled down on Abbott, adding 9.4 million shares (+112.4%) to its portfolio in Q3 2025.
UBS Asset Management: Increased its position by 64.0%, adding 8.16 million shares.
Morgan Stanley: Added 3.4 million shares, representing a 9.7% increase in its stake.
Invesco Ltd.: Increased its holding by 51.0%, adding 4.7 million shares.
The aggressive buying by T. Rowe Price and UBS, both value-oriented institutional managers, indicate a belief that the market is overreacting to the nutrition headwinds and underestimating the long-term value of the Exact Sciences acquisition.
JPMorgan Chase & Co: Conducted a massive reduction, removing 9.92 million shares (-25.2%) from its portfolio.
Polen Capital Management: Reduced its position by 3.2 million shares (-30.5%).
The exit by JPMorgan may reflect a broader sector rotation or concerns about the near-term dilutive impact of the Exact Sciences merger on GAAP earnings. Furthermore, internal insider activity has been exclusively selling, with CFO Philip Boudreau and SVP Eric Shroff selling a combined 7,136 shares over the last six months. While insider sales can be motivated by various personal reasons, the lack of insider buying during the recent dip is a factor for cautious investors to monitor.
Relative Execution: Why Abbott Outperforms in a Crowded Field
The core of the bull case for Abbott is its relative execution. Unlike pure-play medtech companies that are vulnerable to single-market shifts (e.g., Edwards Lifesciences' reliance on TAVR), Abbott's diversified model allows it to absorb shocks. In Q4 2025, the exceptional performance of the medical device segment (10.4% organic growth) more than offset the temporary softness in nutrition.
When compared to its peers, Abbott's execution in the diabetes space is particularly superior. The Libre 3 system has maintained its market-leading position through continuous iteration and a focus on affordability and user experience, consistently outgrowing competitors. In Electrophysiology, the decision to offer a "toolbox" approach rather than a single technology has allowed Abbott to navigate the PFA transition more effectively than those who committed purely to one energy source.
Conclusion
The core of the investment thesis for Abbott Laboratories is not that "the multiple might go up," but that the current price fails to reflect the reality of the business's components. At 18.5x forward earnings, investors are paying for the stability of a Nutrition and Branded Generic business while receiving a world-class Medical Device innovator and a leading Precision Oncology platform as a "free" bonus.
While the five-year per-share growth has been limited, the forward-looking guidance for 2026, projecting 7% organic sales growth and 10% adjusted EPS growth, signals a re-acceleration. Whether through flawless execution (Path A) or potential future structural separation (Path B), the sum-of-the-parts value of Abbott Laboratories far exceeds its current market price. For the long-term investor, Abbott represents a rare opportunity to acquire a high-quality, innovation-driven "Danaher-like" business at a significant conglomerate discount.
View Comments
- BSX Q1 Neuromodulation Sales Rise 15% Y/Y: What Lies Behind the Growth?
May 8, 2026
Boston Scientific’s BSX Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. This segment reflects the company’s long-term commitment to gain leadership through innovation and targeted acquisitions, along with strategies to sustain and accelerate growth across neuromodulation therapies.
Neuromodulation delivered a strong quarter, with organic sales increasing 15% and the comprehensive portfolio posting low double-digit growth. The pain management business grew in the mid-teens, supported partially by a strong contribution from the acquisition of Nalu (completed in late January 2026).
Intracept continued to gain momentum, driven by compelling five-year clinical data demonstrating its long-term efficacy and cost-effectiveness in treating chronic low back pain. Within DBS, adoption of the Cartesia X leads remained strong, while the Illumina 3D programming algorithm saw accelerating uptake across the United States.
Boston Scientific continues to invest in neuromodulation platforms while strengthening its commercial capabilities. The Neuromodulation segment showed improvement, supported by organic contributions from acquisitions such as Relievant and Axonics in 2025. Management expects the Neuromodulation business to grow faster than the broader market over time.
Updates on BSX’s Neuromodulation Competitors
NeuroPace NPCE delivered a strong neuromodulation business performance in fourth-quarter 2025, driven by continued adoption of its responsive neurostimulation (RNS) platform for drug-resistant epilepsy. The company also accelerated development of AI-enabled neuromodulation tools like Seizure ID — an AI-driven platform designed to analyze intracranial EEG recordings, identify seizure activity, and improve physician workflow efficiency.
Medtronic's MDT Neuromodulation business reported 4% growth in the fiscal third quarter, with the ongoing rollout of its Inceptiv spinal cord stimulation (SCS) system and BrainSense adaptive DBS (aDBS) platforms. Inceptiv spinal cord stimulation system is the smallest and thinnest closed-loop SCS device available and offers best-in-class MRI compatibility. With neuromodulation systems’ adoption expanding across major geographies, the company remains well positioned for sustained momentum and long-term leadership in neuromodulation and neurosurgical innovation.
BSX Stock Price Performance
Shares of Boston Scientific have lost 45.2% over the past year compared with the industry’s decline of 29%. The S&P 500 composite has grown 35.4% in the same period.
Story Continues
Zacks Investment Research
Image Source: Zacks Investment Research
Boston Scientific’s Valuation
From a valuation standpoint, BSX trades at a forward 12-month price-to-earnings ratio (P/E) of 3.76X, above the industry median of 3.09X.Zacks Investment Research
Image Source: Zacks Investment Research
BSX Stock Consensus Estimate Trend
The Zacks Consensus Estimate for BSX’s earnings has moved south 2% over the past 30 days.Zacks Investment Research
Image Source: Zacks Investment Research
BSX stock currently has a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boston Scientific Corporation (BSX) : Free Stock Analysis Report
Medtronic PLC (MDT) : Free Stock Analysis Report
NeuroPace, Inc. (NPCE) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- BSX Q1 Neuromodulation Sales Rise 15% Y/Y: What Lies Behind the Growth?
May 8, 2026 · zacks.com
Boston Scientific's Neuromodulation unit posts 15% organic sales growth in Q1, fueled by pain management gains, the acquisition of Nalu and momentum in Intracept.
- BSX Fairly Valued by DCF at $51
May 8, 2026 · gurufocus.com
On May 08, 2026, we delve into the DCF analysis for Boston Scientific Corp (BSX), a company that has faced significant price performance challenges recently. Th
